Global Health Ventures Inc.
OTC Bulletin Board : GHLV

Global Health Ventures Inc.

April 08, 2010 09:25 ET

Global Health Ventures to Close $500,000 Private Placement

VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 8, 2010) - Global Health Ventures Inc. (OTCBB:GHLV) (the "Company") is pleased to announce that, it has completed a non-brokered private placement using Regulations S ("Reg S") Exemption from the registration statement. The Company issued 625,000 units at a price of $0.80 per unit for gross proceeds of $500,000. Each unit consists of one common share and one share purchase warrant. Each share purchase warrant is exercisable into one additional common share of the Company at a price of $1.20 per share until April 08, 2015.

"We are very excited for this additional funding and as a result of the closing of the new financing, we expect the Company to have sufficient funds to complete its ongoing bioequivalent clinical trials studies of its male sexual enhancement drug, X-Excite" said Dr. Hassan Salari, President & CEO of Global Health.

The shares and warrants issued in this private placement were not and will not be registered under the United States Securities Act of 1933 and may not be offered or sold in the absent of registration or an applicable exemption from the registration requirements of the Securities Act of 1933.

About Global Health Ventures

Global Health Ventures is a specialty pharma focused on the life style products. The company has a new proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastro-intestinal system, a process that can greatly reduce side effects associated with the drug. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach blood stream rapidly, producing maximal effect and having less of the unwanted side effects which are associated with the standard oral administration route drugs. X-Excite is presently in clinical trials in Europe.

Notice Regarding Forward Looking Statements - This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products... Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.

Contact Information